ZL 1503
Alternative Names: ZL-1503Latest Information Update: 18 Jun 2025
At a glance
- Originator ZAI Lab
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 31 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis
Most Recent Events
- 13 Jun 2025 ZAI Lab announces intention to submit IND to Regulatory authorities for Atopic dermatitis by the end of year 2025
- 13 Jun 2025 Pharmacokinetics, pharmacodynamics and adverse events data from preclinical studies in atopic dermatitis released by ZAI Lab
- 08 May 2025 Zai Labs plans a global phase I trial in Atopic dermatitis(Parenteral)